It has been previously reported that KRAS mutations regulate growth factor shedding following chemotherapy treatment via the MEK/Erk/ADAM17 signalling axis and contribute to drug resistance in CRC tumours (Van Schaeybroeck et al., 2011). Here, KRAS is linked to colorectal carcinoma.